---
url: "https://dfylegitscript.com/blog/the-post-purchase-surface-your-application-includes"
title: "Everything the patient reads after they pay is still your marketing"
description: "A LegitScript reviewer can reach the confirmation email, the patient portal, the dosing instructions and the card that ships in the box, and those four surfaces are usually written by different people to no standard at all, which is where a corrected claim most often survives."
published: "2026-07-04T11:12:40+00:00"
modified: "2026-07-04T11:12:40+00:00"
---

# Everything the patient reads after they pay is still your marketing

A LegitScript reviewer can reach the confirmation email, the patient portal, the dosing instructions and the card that ships in the box, and those four surfaces are usually written by different people to no standard at all, which is where a corrected claim most often survives.

## Key takeaways

- Everything a patient reads after paying is reachable by anybody who buys once, which includes a reviewer, so the confirmation email and the portal are marketing under review.
- The post-purchase surface is usually written by different people to no standard at all, which is where a claim corrected on the website quietly survives.
- Printed inserts are the slowest asset to correct, because lead times and physical stock mean a wrong leaflet keeps shipping for months after the copy changed.
- A support macro has to carry the answer rather than the rule, since a patient asking whether a dose is safe gets whatever the agent improvises instead.

Brands audit the funnel. Almost nobody audits what happens after the payment,
and that is where a surprising amount of the claims risk lives, because
post-purchase copy is written by operations, by support, by a fulfilment partner
and by whoever set up the email tool, and none of them was given the rules.

It is also the copy most likely to be years old.

## The surfaces

**The confirmation and shipping emails.** Written once, at launch, describing
the product in the voice the brand had then.

**The onboarding sequence.** Dosing guidance, what to expect, what is normal.
This is clinical content sent at scale, and it is frequently written by a
marketer.

**Whatever is in the box.** A welcome card, a dosing schedule, a leaflet, a
tracker, a referral card. Printed, so it is the hardest thing on this list to
correct, and it is the one nobody remembers exists.

**The patient portal.** Product descriptions, plan management, messages, and
often the clearest statement anywhere of what the patient is actually taking.

**Support replies.** Macros and free-typed answers, which is where a nervous
customer gets reassured with a comparison to the brand-name drug in writing.

**Retention and win-back messaging.** Written to fight churn, which is a brief
that pulls hard toward outcome claims.

## Why it matters more than it looks

Three reasons.

The first is reachability. A reviewer can buy from you, and a great deal of what
follows arrives without any further permission. So can anybody else.

The second is that this content is often the most clinically specific thing the
business publishes. Dosing instructions, escalation guidance and what to do
about a side effect are clinical communications, and they should carry a
clinician's approval rather than a copywriter's.

The third is durability. When a claim is corrected on the website, it usually
survives here, because nobody thought of the box.

## The pharmacy boundary again

Some of what arrives in the package comes from the pharmacy rather than from
you, and some of it carries information the patient will read as coming from
your brand.

Establish which is which. Ask what the pharmacy encloses, get a copy, and read
it alongside your own material for anything that contradicts it, particularly
about dosing, storage and what to do if something goes wrong. Two sets of
instructions that disagree is a patient safety problem before it is a
compliance one.

## What good looks like

**One owner for clinical communications.** Everything that tells a patient what
to do with a medicine goes through a named clinician before it ships, including
emails, portal copy and printed inserts.

**The claims allowlist applied everywhere.** Same document, same approved
phrasings, extended to support macros and packaging.

**A dated inventory.** Every post-purchase asset, when it was last reviewed, and
who owns it. This is what makes the next correction cheap.

**A rule for printed material.** Long lead times and physical stock mean a
change takes months, so printed inserts should carry the least perishable copy
of anything you publish. Keep claims out of the box entirely and put them
nowhere at all.

## The support macro problem, specifically

Worth separating because it is the single most common finding in this area.

Support agents are measured on resolution and empathy. A worried customer asking
whether the medicine is the same as the branded one gets an answer designed to
reassure, and the reassuring answer is the forbidden one. It is written, it is
stored, and it is repeated hundreds of times.

Fix it by supplying the answer rather than the prohibition. Write the approved
response to the five questions customers actually ask, put them in the macro
library, and review them when the allowlist changes. An agent given a good
answer uses it. An agent given a rule improvises.

## The referral and loyalty mechanics

Post-purchase is where brands ask customers to recruit other customers, and the
copy written for that job pulls hard in the wrong direction.

A referral card asking a patient to tell a friend how much weight they lost is
commissioning a testimonial with an outcome claim in it. A loyalty programme
that rewards continued treatment sits awkwardly beside a clinical model in which
a prescriber may decide treatment should stop. A "share your results" prompt
generates exactly the user content
[your review widget](/blog/testimonials-reviews-and-before-and-after-imagery)
then displays.

None of these is unusable. They need writing to ask for something else: tell a
friend about the service, share what the consultation was like, invite somebody
to get assessed. The mechanic survives, the claim does not.

## The pause, the decline and the discontinuation message

Three messages every telehealth brand sends and almost none writes carefully.

When a prescriber declines, the message is doing two jobs at once: explaining a
clinical decision and handling a refund. It should say clearly that a clinician
made a decision, what happens to the money, and what the patient can do next,
without implying the decision was administrative.

When a patient pauses or cancels, the win-back message that follows is written
by retention and reads as though the medicine is a product they have stopped
buying rather than a treatment a clinician was supervising.

And when treatment should stop for clinical reasons, there needs to be a message
for that at all, written by a clinician, rather than the patient simply falling
out of a billing cycle.

## An audit you can run in a day

Buy your own product, on a real card, and keep everything.

- Read every email in the first thirty days against the claims allowlist.
- Photograph everything in the box, including the pharmacy's own material.
- Log into the portal and read every product description and plan screen.
- Ask support your three hardest questions from a customer address and read what
  comes back.
- Trigger the cancellation flow and read the win-back sequence that follows.

Most brands find at least one claim they thought they had removed months ago,
which is the argument
[the compounded marketing rules](/blog/marketing-compounded-glp-1-products-without-a-misbranding-problem)
make about sweeping every channel rather than the product page.

## Where it fits in the file

It is part of the website audit even though none of it is on the website.
[A complete application file](/blog/what-a-complete-legitscript-application-file-looks-like)
covers every page a patient can reach, and after the payment the patient reaches
a great deal more than a page.

## Frequently asked questions

### Does a reviewer really see my post-purchase emails?

Anybody who buys from you receives them, and that includes people assessing the business. The practical planning assumption is that everything a customer receives is readable by a reviewer, a platform and a regulator.

### Who should write dosing instructions and onboarding content?

A clinician should approve anything that tells a patient what to do with a medicine, including emails, portal copy and printed inserts. It is clinical communication sent at scale, and it is routinely drafted by marketing without review.

### What should go on printed inserts?

As little claim content as possible. Printed material has a long lead time and existing stock, so a correction takes months, which makes the box the worst place to keep anything that might need changing.

## Disclaimer

LegitScript is a trademark of LegitScript LLC. VeriScripts is an independent application-preparation service. It is not affiliated with, endorsed by, or certified by LegitScript LLC, and claims no sponsorship or partnership with it. We prepare, submit, and manage the application; LegitScript alone decides whether certification is granted. "LegitScript" is used here only to name the certification these applications are for.